LONGEVERON INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.75 USD | +4.79% |
|
-8.85% | -87.13% |
| 15/04 | Top Premarket Gainers | MT |
| 08/04 | Top Premarket Gainers | MT |
| Sales 2024 * | - | Sales 2025 * | 66.67K 5.56M | Capitalization | 12.6M 1.05B |
|---|---|---|---|---|---|
| Net income 2024 * | -22M -1.83B | Net income 2025 * | -21M -1.75B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 189 x |
| P/E ratio 2024 * |
-0.25
x | P/E ratio 2025 * |
-0.52
x | Employees | 24 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 56.43% |
More Fundamentals
* Assessed data
More news
Latest transcript on Longeveron Inc.
More recommendations
More press releases
| 1 day | +0.57% | ||
| 1 week | -8.85% | ||
| Current month | -46.15% | ||
| 1 month | -49.08% | ||
| 3 months | -78.12% | ||
| 6 months | -90.79% | ||
| Current year | -87.13% |
1 week
1.60
2.06
1 month
1.605.47
Current year
1.6014.30
1 year
1.6044.00
3 years
1.60450.00
5 years
1.60450.00
10 years
1.60450.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 01/23/01 | |
Joshua Hare
FOU | Founder | 61 | 09/14/09 |
Lisa Locklear
DFI | Director of Finance/CFO | 64 | 31/23/31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joshua Hare
FOU | Founder | 61 | 09/14/09 |
Jeffrey Pfeffer
BRD | Director/Board Member | 77 | 09/23/09 |
Cathy Ross
BRD | Director/Board Member | 56 | 12/21/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.75 | +4.79% | 373,405 |
| 25/24/25 | 1.67 | -2.91% | 322,087 |
| 24/24/24 | 1.72 | -5.49% | 323,839 |
| 23/24/23 | 1.82 | -2.67% | 275,885 |
| 22/24/22 | 1.87 | -2.60% | 485,013 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimerâs disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
Calendar
10/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.75
USD
Average target price
30.05
USD
Spread / Average Target
+1,617.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -87.13% | 12.6M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- LGVN Stock
